Shares of SMS Pharmaceuticals Ltd skyrocketed more than 10% on Thursday, 28 August, after the company received an Establishment Inspection Report (EIR) with a No Action Indicated status for its Central Laboratory Analytical Services in Hyderabad. 

SMS Pharmaceuticals gets a clean USFDA inspection report. The company announced the successful completion of a US Food and Drug Administration (USFDA) inspection at its Central Laboratory Analytical Services in Gagillapur, Hyderabad.

The inspection, which lasted from 23 June to 25 June 2025, resulted in zero Form 483 observations, according to an exchange filing.  The company has now received the Establishment Inspection Report (EIR) with a “No Action Indicated” (NAI) status, certifying that the audit is complete.

The company launched its backwards integration project, which is a vital step toward strengthening our supply chain and boosting cost savings, according to executive director P. Vamsi Krishna. “The project has delivered the desired outcomes in quality and performance, and we are now scaling up production. With full backwards integration now in place for our key APIs, we expect to see a meaningful improvement in margins over the next few quarters.”

The company manufactures active pharmaceutical ingredients (APIs) and intermediates. It has a research and development centre in Gagillapur, Hyderabad, and manufacturing facilities in Bachupally, Hyderabad, and Kandivalasa village in the Vizianagaram district of Andhra Pradesh.

However, at 3:13 pm, the shares of SMS Pharma shed all its early gains and were trading 1.84% lower at Rs 227.16 on NSE.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!